MediWound Reports Third Quarter 2026 Financial Results and Provides Corporate Update
EscharEx® Phase III VALUE Trial Advancing; Interim Assessment and Enrollment Completion Expected by
EscharEx® Phase III VALUE Trial Advancing; Interim Assessment and Enrollment Completion Expected by